Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

• Published in: BMC neurology Vol. 19; no. 1; pp. 191 - 8
• Main Authors: Loo, Li Shen, Plato, Brian M., Turner, Ira M., Case, Michael G., Raskin, Joel, Dowsett, Sherie A., Krege, John H.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.08.2019; BioMed Central; BMC
• Subjects: Adult; Analgesia; Analysis; Benzamides - administration & dosage; Benzamides - adverse effects; Care and treatment; Clinical trials; Double-Blind Method; Female; Headache; Humans; Lasmiditan; Male; Medical research; Middle Aged; Migraine; Migraine Disorders - drug therapy; Pain; Pain management; Phase 3; Piperidines - administration & dosage; Piperidines - adverse effects; Pyridines - administration & dosage; Pyridines - adverse effects; Recurrence; Recurrence (Disease); Rescue; Second dose; Serotonin Receptor Agonists - administration & dosage; Serotonin Receptor Agonists - adverse effects; Recurrence; Rescue; Phase 3; Lasmiditan; Second dose

We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies in which individuals with migraine were randomized to oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo. Study d...